Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nitazoxanide + ribavirin + hydroxychloroquine
- Development stage
- Discontinued
- Lead developer
- Rutgers University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
nitazoxanide + ribavirin + hydroxychloroquine is a triple combination antiviral regimen, also known as TriACT (Triple Combination Antiviral Coronavirus Therapy), being evaluated for the treatment of COVID-19. Developed by Rutgers, The State University of New Jersey, in collaboration with Synavir Corporation, this therapy combines three small molecule drugs with distinct mechanisms of action: nitazoxanide (a thiazolide antiviral), ribavirin (a guanosine analog), and hydroxychloroquine sulfate (an aminoquinoline). The combination was designed based on in vitro studies demonstrating multiplicative antiviral effects against SARS-CoV-2 by targeting different stages of the viral replication life cycle. The regimen is typically administered as a 5-day oral course and has been evaluated in Phase 2 clinical trials to determine its efficacy in reducing viral load and preventing hospitalization in outpatients with early-stage COVID-19.
- Other names
- Triple Combination Antiviral Coronavirus TherapyNTZ + RBV + HCQ
02
Targets
EIF2AK2 (Interferon-induced protein kinase R)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)RdRp (Coronavirus RNA-dependent RNA polymerase)TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on nitazoxanide + ribavirin + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nitazoxanide + ribavirin + hydroxychloroquine.